| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Natalizumab |
| Brand | Tysabri® |
| Indication | For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated. |
| Assessment Process | |
| NCPE assessment re-commenced | 23/01/2007 |
| NCPE assessment completed | 03/04/2007 |
| NCPE assessment outcome | Reimbursement recommended. |
Natalizumab could be considered borderline cost effective in the Irish healthcare setting. In view of the uncertainty surrounding some of the ICERs a follow up review is advised. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.